1. CLRM-15 TRIAL IN PROGRESS: A PHASE 1B/2 STUDY OF GB5121, A NOVEL, HIGHLY SELECTIVE, POTENT, AND CNS-PENETRANT INHIBITOR OF BRUTON'S TYROSINE KINASE (BTKI) FOR RELAPSED/REFRACTORY PRIMARY/SECONDARY CNS LYMPHOMA (R/R PCNSL/SCNSL) AND PRIMARY VITREORETINAL LYMPHOMA (PVRL). (5th August 2022) Authors: Soussain, Carole; Grommes, Christian; Issa, Samar; Ward, Renee; Peterson, Caryn; Cravets, Matt; Mathias, Anita; Sosa, Judith; Kirby, Brian; Ding, Zhaoqing; Yusuf, Isharat; Rose, Mark; Steinberg, Marcos; Tun, Han W Journal: Neuro-oncology advances Issue: Volume 4(2022)Supplement 1 Page Start: i9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The role of the multiprofessional consultant practitioner in supporting workforce transformation in the UK. Issue 2 (2022) Authors: Manley, Kim; Crouch, Robert; Ward, Renee; Clift, Esther; Jackson, Carolyn; Christie, Jane Journal: Advanced journal of professional practice Issue: Volume 3:Issue 2(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Issue 9 (September 2015) Authors: Ravandi, Farhad; Ritchie, Ellen K; Sayar, Hamid; Lancet, Jeffrey E; Craig, Michael D; Vey, Norbert; Strickland, Stephen A; Schiller, Gary J; Jabbour, Elias; Erba, Harry P; Pigneux, Arnaud; Horst, Heinz-August; Recher, Christian; Klimek, Virginia M; Cortes, Jorge; Roboz, Gail J; Odenike, Olatoyosi... Journal: Lancet oncology Issue: Volume 16:Issue 9(2015:Sep.) Page Start: 1025 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Issue 9 (September 2015) Authors: Ravandi, Farhad; Ritchie, Ellen K; Sayar, Hamid; Lancet, Jeffrey E; Craig, Michael D; Vey, Norbert; Strickland, Stephen A; Schiller, Gary J; Jabbour, Elias; Erba, Harry P; Pigneux, Arnaud; Horst, Heinz-August; Recher, Christian; Klimek, Virginia M; Cortes, Jorge; Roboz, Gail J; Odenike, Olatoyosi... Journal: Lancet oncology Issue: Volume 16:Issue 9(2015:Sep.) Page Start: 1025 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗